PMID- 20054294
OWN - NLM
STAT- MEDLINE
DCOM- 20100310
LR  - 20221207
IS  - 1532-6535 (Electronic)
IS  - 0009-9236 (Linking)
VI  - 87
IP  - 3
DP  - 2010 Mar
TI  - KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) polymorphisms affect therapeutic 
      efficacy of repaglinide in Chinese patients with type 2 diabetes.
PG  - 330-5
LID - 10.1038/clpt.2009.242 [doi]
AB  - This study showed that the polymorphisms KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) 
      are associated with a heightened risk of developing type 2 diabetes mellitus 
      (T2DM). We also explored the effects of these polymorphisms on the efficacy of 
      repaglinide therapy in Chinese patients with T2DM. A total of 259 patients with 
      T2DM and 188 healthy controls were genotyped. Forty patients with various 
      genotypes were randomly selected to undergo an 8-week repaglinide treatment 
      regimen. Patients with the G allele of the KCNJ11 Lys23Glu polymorphism showed 
      higher levels of fasting plasma glucose (FPG) and postprandial plasma glucose 
      (PPG) (P < 0.05). After repaglinide treatment, patients with the GA or AA 
      genotype showed higher levels of FPG, PPG, and glycated hemoglobin (HbA(1c)) 
      compared with patients with the GG genotype (P < 0.05). Patients with the C 
      allele of TCF7L2 rs290487(C/T) had higher total cholesterol levels and lower body 
      mass index (BMI) (P < 0.05). In patients with the TT genotype, the drug showed 
      better efficacy with respect to levels of fasting insulin, triglycerides, and 
      low-density lipoprotein cholesterol (LDL-c) than in patients with the CC or CT 
      genotype (P < 0.05). The KCNJ11 and TCF7L2 polymorphisms were associated with 
      repaglinide efficacy.
FAU - Yu, M
AU  - Yu M
AD  - Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, 
      Central South University, Hunan, People's Republic of China.
FAU - Xu, X-J
AU  - Xu XJ
FAU - Yin, J-Y
AU  - Yin JY
FAU - Wu, J
AU  - Wu J
FAU - Chen, X
AU  - Chen X
FAU - Gong, Z-C
AU  - Gong ZC
FAU - Ren, H-Y
AU  - Ren HY
FAU - Huang, Q
AU  - Huang Q
FAU - Sheng, F-F
AU  - Sheng FF
FAU - Zhou, H-H
AU  - Zhou HH
FAU - Liu, Z-Q
AU  - Liu ZQ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20100106
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Blood Glucose)
RN  - 0 (Carbamates)
RN  - 0 (Kir6.2 channel)
RN  - 0 (Piperidines)
RN  - 0 (Potassium Channels, Inwardly Rectifying)
RN  - 0 (TCF Transcription Factors)
RN  - 0 (TCF7L2 protein, human)
RN  - 0 (Transcription Factor 7-Like 2 Protein)
RN  - 3KX376GY7L (Glutamic Acid)
RN  - 668Z8C33LU (repaglinide)
RN  - K3Z4F929H6 (Lysine)
SB  - IM
MH  - Adult
MH  - Alleles
MH  - Amino Acid Substitution/genetics
MH  - Asian People/*genetics
MH  - Blood Glucose/drug effects/genetics
MH  - Carbamates/*therapeutic use
MH  - Diabetes Mellitus, Type 2/blood/drug therapy/*genetics
MH  - Female
MH  - Glutamic Acid/*genetics
MH  - Humans
MH  - Lysine/*genetics
MH  - Male
MH  - Middle Aged
MH  - Piperidines/*therapeutic use
MH  - Polymorphism, Genetic/*genetics
MH  - Potassium Channels, Inwardly Rectifying/*genetics
MH  - Risk Factors
MH  - TCF Transcription Factors/*genetics
MH  - Transcription Factor 7-Like 2 Protein
MH  - Treatment Outcome
EDAT- 2010/01/08 06:00
MHDA- 2010/03/11 06:00
CRDT- 2010/01/08 06:00
PHST- 2010/01/08 06:00 [entrez]
PHST- 2010/01/08 06:00 [pubmed]
PHST- 2010/03/11 06:00 [medline]
AID - clpt2009242 [pii]
AID - 10.1038/clpt.2009.242 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 2010 Mar;87(3):330-5. doi: 10.1038/clpt.2009.242. Epub 2010 
      Jan 6.